Physician profile
Eric Fox
NPI 1417310038
$16,180.28
in general payments reported to CMS, 2019-2025
66 companies · $4,426 in 2025
The $4,426 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $411 · 2021: $123 · 2022: $547 · 2023: $4,256 · 2024: $5,596 · 2025: $4,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $2,475 · Honoraria: $200 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,500.91 |
| Consulting Fee | $2,475.00 |
| Honoraria | $200.00 |
| Education | $101.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,311.69 | 2023-2025 | Imbruvica, Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals Lp | $2,127.91 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Pfizer INC. | $901.90 | 2019-2025 | |
| Daiichi Sankyo INC. | $860.23 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $658.66 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $640.76 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $606.38 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $588.51 | 2024-2025 | |
| Incyte Corporation | $546.01 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $477.04 | 2022-2025 | Vyloy, Xospata, Xtandi |
| E.R. Squibb & Sons, L.L.C. | $444.69 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Eisai INC. | $429.43 | 2023-2025 | |
| Exelixis INC. | $418.19 | 2023-2025 | Cabometyx |
| Celgene Corporation | $353.08 | 2019-2025 | Reblozyl, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $352.93 | 2020-2025 | Onivyde, Somatuline Depot |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.